Real‐World Delivery of Rucaparib to Patients with Ovarian Cancer: Recommendations Based on an Integrated Safety Analysis of ARIEL2 and Study 10

Treatment options for women with recurrent ovarian cancer who have received two or more prior lines of chemotherapy have recently expanded with the U.S. Food and Drug Administration (FDA) and European Commission (EC) approvals of the poly(ADP‐ribose) polymerase (PARP) inhibitor rucaparib. As more on...

Descripción completa

Detalles Bibliográficos
Autores principales: Drew, Yvette, Kristeleit, Rebecca S., Oaknin, Ana, Ray‐Coquard, Isabelle, Haris, Noor Md., Swisher, Elizabeth M.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley & Sons, Inc. 2019
Materias:
Gynecologic Oncology
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6964123/
https://www.ncbi.nlm.nih.gov/pubmed/31575788
http://dx.doi.org/10.1634/theoncologist.2019-0229

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6964123/
https://www.ncbi.nlm.nih.gov/pubmed/31575788
http://dx.doi.org/10.1634/theoncologist.2019-0229

Ejemplares similares